Implicaciones de la arginina-vasopresina y de la copeptina en la gestación normal y en la preeclampsia / Implications of arginine-vasopressin and copeptin in normal gestation and in pre-eclampsia

La preeclampsia representa una complicación específica de hipertensión del embarazo, que aparece de novo después de la 20 semana de gestación, acompañada de proteinuria y/o disfunción orgánica materna o útero-placentaria. A pesar de una etiopatogenia incierta, la alteración en el remodelado vascular de la arteria espiral e isquemia placentaria es la hipótesis más generalizada. El hallazgo de niveles elevados de copeptina, en mujeres con preeclampsia respecto a gestantes normales, ha puesto en valor la implicación de la arginina-vasopresina en la etiopatogenia de esta complicación. En este trabajo se considera su utilidad como marcador de preeclampsia a través de la revisión de los principales estudios efectuados con esta molécula.(AU)

Preeclampsia represents a specific complication of pregnancy hypertension, which appears de novo after the 20th week of gestation, accompanied by proteinuria and/or maternal or utero-placental organ dysfunction. Despite an uncertain etiopathogenesis, impaired vascular remodeling of the spiral artery and placental ischemia is the most widespread hypothesis. The finding of elevated levels of copeptin in women with preeclampsia compared to normal pregnant women has valued the involvement of arginine vasopressin in the etiopathogenesis of this complication. In this paper, its usefulness as a marker of preeclampsia is considered through the review of the main studies carried out with this molecule.(AU)

[Implications of arginine-vasopressin and copeptin in normal gestation and in pre-eclampsia]. / Implicaciones de la arginina-vasopresina y de la copeptina en la gestación normal y en la preeclampsia.

Preeclampsia represents a specific complication of pregnancy hypertension, which appears de novo after the 20th week of gestation, accompanied by proteinuria and/or maternal or utero-placental organ dysfunction. Despite an uncertain etiopathogenesis, impaired vascular remodeling of the spiral artery and placental ischemia is the most widespread hypothesis. The finding of elevated levels of copeptin in women with preeclampsia compared to normal pregnant women has valued the involvement of arginine vasopressin in the etiopathogenesis of this complication. In this paper, its usefulness as a marker of preeclampsia is considered through the review of the main studies carried out with this molecule.

Anemia renal: tratamientos actuales y moléculas emergentes / Renal anemia: current treatments and emerging molecules

La anemia es una complicación frecuente de la enfermedad renal cuya prevalencia aumenta a medida que progresa la enfermedad, empeora la calidad de vida de pacientes y aumenta la morbimortalidad. El fundamento actual para tratar la anemia renal se basa en empleo de agentes estimuladores de eritropoyesis, la suplementación con hierro y en menor medida, el uso de trasfusiones. La estimulación de la síntesis endógena de eritropoyetina y la mejora de la disponibilidad del hierro, a través de la inhibición de prolil-hidroxilasa del factor inducible por la hipoxia (PH-HIF), representa una nueva alternativa oral de tratamiento de la anemia renal. Los ensayos clínicos con inhibidores PH-HIF han demostrado su eficacia en mantener niveles de hemoglobina objetivo. Sin embargo, aspectos concernientes a la seguridad a largo plazo se encuentran pendientes de clarificar. En conclusión, los avances en la patogenia de anemia renal permiten disponer de tratamientos actuales para tratar la anemia renal y el desarrollo de nuevas moléculas, basadas en la inhibición de PH-HIF, representa una nueva alternativa eficaz para anemia asociada con enfermedad renal, especialmente en pacientes con resistencia a agentes estimuladores de eritropoyesis (AU)

Anemia is a common complication of kidney disease and the prevalence increases as the disease progresses. It worsens the quality of life of patients and increases morbidity and mortality. The current rationale for treating renal anemia is based on the use of erythropoiesis-stimulating agents, iron supplementation and, to a lesser extent, the use of transfusions. Stimulation of endogenous erythropoietin synthesis and improvement of iron availability, through inhibition of prolyl-hydroxylase-hypoxia-inducible factor (PH-HIF), represents a new oral alternative for renal anemia treatment. Clinical trials with PH-HIF inhibitors have demonstrated their efficacy in maintaining target hemoglobin levels. However, aspects concerning long-term safety are pending a clarification. In conclusion, advances in the pathogenesis of renal anemia make it possible to have current treatments to treat renal anemia. The development of new molecules, based on the inhibition of PH-HIF, represents a new effective alternative for anemia associated with kidney disease, especially in patients with resistance to erythropoiesis-stimulating agents (AU)

Diagnóstico inesperado de nefronoptisis en estudio genético de hipertensión por diagnóstico histológico de nefroangioesclerosis benigna evolucionada en paciente joven caucásico / Unexpected diagnosis of nephronopthisis in the genetic study of hypertension due to histological diagnosis of benign nephroangioesclerosis evolved in a young caucasian patient

Se presenta el caso de un paciente joven de raza caucásica, con una enfermedad renal de causa no clara, con un diagnóstico final establecido por biopsia renal de nefroangioesclerosis benigna evolucionada. Debido a la posibilidad de haber tenido hipertensión arterial en edad pediátrica (sin estudio ni tratamiento), con los hallazgos de biopsia renal, el estudio genético de hipertensión mostró polimorfismos de riesgo en los genes APOL1 y MYH9 y, además, un diagnóstico inesperado de una deleción completa del gen NPHP1 en homocigosis, asociada al desarrollo de nefronoptisis. En conclusión, este caso ilustra la importancia de hacer estudio genético, sobre todo en pacientes jóvenes con enfermedad renal de causa no clara, incluso teniendo un diagnóstico histológico de nefroangioesclerosis. (AU)

We present the case of a young Caucasian patient with renal disease of unclear cause, with a final diagnosis of advanced benign nephroangiosclerosis established by renal biopsy. Due to the possibility of having hypertension in pediatric age (without study or treatment), with the renal biopsy findings, the genetic study showed polymorphisms risk in the APOL1 and MYH9, and also an unexpected diagnosis of a complete deletion of the NPHP1 gene in homozygosis, associated with the development of nephronophthisis. In conclusion, this case illustrates the importance of carrying out a genetic study in youngs patients with renal disease unclear cause, even having a histological diagnosis of nephroangiosclerosis. (AU)

Renal anemia: current treatments and emerging molecules.

Anemia is a common complication of kidney disease and the prevalence increases as the disease progresses. It worsens the quality of life of patients and increases morbidity and mortality. The current rationale for treating renal anemia is based on the use of erythropoiesis-stimulating agents, iron supplementation and, to a lesser extent, the use of transfusions. Stimulation of endogenous erythropoietin synthesis and improvement of iron availability, through inhibition of prolil-hydroxilase-hypoxia-inducible factor (PH-HIF), represents a new oral alternative for renal anemia treatment. Clinical trials with PH-HIF inhibitors have demonstrated their efficacy in maintaining target hemoglobin levels. However, aspects concerning long-term safety are pending a clarification. In conclusion, advances in the pathogenesis of renal anemia make it possible to have current treatments to treat renal anemia. The development of new molecules, based on the inhibition of PH-HIF, represents a new effective alternative for anemia associated with kidney disease, especially in patients with resistance to erythropoiesis-stimulating agents.

Nephroangiosclerosis: an update / Nefroangioesclerosis: actualización

Nephroangiosclerosis or kidney disease that accompanies chronic essential arterial hypertension has been known for more than a hundred years. The definitive diagnosis is established by renal biopsy, which is reserved for doubtful cases or atypical presentation, being in most cases a presumptive clinical diagnosis. The objective of this review is to analyse the main controversies that currently exist related to nephroangiosclerosis: inaccuracy in epidemiological aspects (prevalence and incidence unknown), diagnostic difficulties and lack of correlation studies between clinical data and histopathology, progression factors in Caucasians. Currently, with advances in genetic studies in hypertension, not using or redefining the term hypertensive kidney disease for another condition such as nephropathy related to the present genetic alteration is being considered. (AU)

La nefroangioesclerosis o enfermedad renal que acompaña a la hipertensión arterial esencial crónica, es una entidad conocida desde hace más de 100 años. El diagnóstico definitivo se establece por biopsia renal, la cual se reserva para casos dudosos o presentación atípica, siendo en la mayoría de casos un diagnóstico clínico de presunción. El objetivo de esta revisión es analizar las principales controversias que existen actualmente relacionadas con la nefroangioesclerosis: inexactitud en aspectos epidemiológicos (prevalencia e incidencia real desconocida), dificultades diagnósticas y falta de estudios de correlación entre datos clínicos e histopatología, factores de progresión en raza caucásica. Actualmente con los avances en estudios genéticos en hipertensión se está planteando abandonar o redefinir el término de enfermedad renal hipertensiva por otro como nefropatía relacionada con la alteración genética presente. (AU)

[Unexpected diagnosis of nephronopthisis in the genetic study of hypertension due to histological diagnosis of benign nephroangioesclerosis evolved in a young caucasian patient]. / Diagnóstico inesperado de nefronoptisis en estudio genético de hipertensión por diagnóstico histológico de nefroangioesclerosis benigna evolucionada en paciente joven caucásico.

We present the case of a young Caucasian patient with renal disease of unclear cause, with a final diagnosis of advanced benign nephroangiosclerosis established by renal biopsy. Due to the possibility of having hypertension in pediatric age (without study or treatment), with the renal biopsy findings, the genetic study showed polymorphisms risk in the APOL1 and MYH9, and also an unexpected diagnosis of a complete deletion of the NPHP1 gene in homozygosis, associated with the development of nephronophthisis. In conclusion, this case illustrates the importance of carrying out a genetic study in youngs patients with renal disease unclear cause, even having a histological diagnosis of nephroangiosclerosis.

Nephroangiosclerosis: an update.

Nephroangiosclerosis or kidney disease that accompanies chronic essential arterial hypertension has been known for more than a hundred years. The definitive diagnosis is established by renal biopsy, which is reserved for doubtful cases or atypical presentation, being in most cases a presumptive clinical diagnosis. The objective of this review is to analyse the main controversies that currently exist related to nephroangiosclerosis: inaccuracy in epidemiological aspects (prevalence and incidence unknown), diagnostic difficulties and lack of correlation studies between clinical data and histopathology, progression factors in Caucasians. Currently, with advances in genetic studies in hypertension, not using or redefining the term hypertensive kidney disease for another condition such as nephropathy related to the present genetic alteration is being considered.

[Acute myocardial infarction and severe hypokalaemia due to liquorice consumption during COVID-19 confinement]. / Infarto agudo de miocardio e hipopotasemia severa por consumo de regaliz durante el confinamiento por COVID-19.

Liquorice is one of the oldest known herbs with medicinal properties and comprises up to 300 active compounds. It has been used for millennia for its digestive, anti-inflammatory and anti-infective properties. However, its possible toxic effects were described only a few years ago and there is growing interest in the side effects associated with chronic consumption. The main active component of liquorice is the prodrug glycyrrhizin and its active metabolite glycyrrhetic acid. It is a rare cause of hypokalaemia due to suppression of the renin-angiotensin-aldosterone axis, causing pseudohyperaldostenonism (PHA). We describe a rare case of secondary acute myocardial infarction in a patient with chronic consumption of liquorice.

Incidencia de nefropatía por contraste en pacientes sometidos a tomografía computarizada: ¿qué factores la condicionan? / Factors affecting the incidence of contrast-induced nephropathy in patients undergoing computed tomography

Objetivo: Analizar la incidencia de nefropatía por contraste en una cohorte de pacientes sometidos a tomografía computarizada (TC) con contraste yodado intravenoso. Valorar los resultados de la nefroprotección con N-acetilcisteína. Pacientes y métodos: Estudio observacional prospectivo, entre los meses de marzo y julio de 2016. Los pacientes seleccionados tenían programada una TC. Se incluyeron los primeros 5 pacientes de cada día, que aceptaban participar y firmaban el consentimiento informado. Se registraron antecedentes cardiovasculares, tratamientos crónicos e indicación de la TC. Se determinó la creatinina y la urea en sangre pre-TC y pos-TC. El filtrado glomerular se determinó por MDRD-4 (Modification of Diet in Renal Disease). Respecto al contraste, se analizó tipo y dosis. Se registró el uso de N-acetilcisteína anterior a la TC. Estadística: SPSS 15.0(R) utilizando comparación de medias y proporciones. Significación: p < 0,05. Resultados: No se detectó ninguna NC en 202 pacientes estudiados. Datos globales: edad: 63,92 ± 12 años (rango 22-87); 57,4% varones; 21,8% diabéticos; 39,6% hipertensos; 176 pacientes tenían MDRD4 ≥ 60 ml/min/1,73 m2 (89,45 ± 14, rango 62,36-134,14) y 26 MDRD4 < 60 ml/min/1,73 m2 (45,38 ± 11, rango 9,16-58,90). La principal indicación de TC fue oncológica (81,2%). El único contraste administrado fue iopamidol, en dosis de 107,83 ± 11 ml (rango 70-140). El intervalo de días entre analíticas fue de 4,06 ± 1 días. Solo en 13 pacientes se administró N-acetilcisteína: en 9 con MDRD < 60 ml/min/1,73 m2 y en 4 con MDRD4 > 60 ml/min/1,73 m2 (p = 0,000). Conclusiones: La incidencia de NC es no significativa en la cohorte estudiada con un filtrado glomerular superior a 30 ml/min/1,73 m2: la realización de TC de forma "programada", utilizando un contraste yodado "no iónico" en dosis relativamente baja, es un factor que quizás explique estos resultados favorables

Objective: To analyze the incidence of contrast-induced nephropathy in a cohort of patients undergoing computed tomography (CT) with intravenous iodinated contrast material. To evaluate the efficacy of N-acetylcysteine in preventing contrast-induced nephropathy. Patients and methods: This prospective observational study was carried out in the months comprising March 2016 through July 2016. We selected the first five patients scheduled to undergo CT examination each day who agreed to participate and signed the informed consent form. We recorded patients' cardiovascular histories, chronic treatments, and indications for the CT examination. We measured blood levels of creatinine and urea before and after the CT examination. We used the Modification of Diet in Renal Disease (MDRD-4) equation to estimate the glomerular filtration rate. We analyzed the type and dose of contrast material. We recorded whether N-acetylcysteine was administered before the CT examination. We used SPSS 15.0(R) to compare means and proportions. Statistical significance was set at p < 0.05. Results: No incidents of contrast-induced nephropathy were detected in any of the 202 patients included [mean age, 63.92 ± 12 years (range 22-87); 57.4% male; 21.8% diabetic; 39.6% hypertensive; 87.1% had MDRD4 ≥ 60 ml/min/1.73 m2 (89.45 ± 14, range 62.36-134.14) and 12.9% had MDRD4 < 60 ml/min/1.73 m2 (45.38 ± 11, range 9.16-58.90)]. The most common indication for CT examinations was oncologic (81.2%). The only contrast agent administered was iopamidol; the mean dose was 107.83 ± 11 ml (range 70-140). The mean interval between pre-CT and post-CT laboratory tests was 4.06 ± 1 days. Only 13 patients received N-acetylcysteine; 9 of these had MDRD < 60 ml/min/1.73 m2 and 4 had MDRD4 ≥ 60 ml/min/1.73 m2 (p = 0.000). Conclusions: The incidence of contrast-induced nephropathy was not significant in patients with glomerular filtration rates greater than 30 ml/min/1.73 m2: these favorable results might be due to analyzing only scheduled examinations and to using relatively low doses of a "nonionic" iodinated contrast agent

Recidiva tardía de feocromocitoma con metástasis como causa de hipertensión arterial severa en mujer intervenida quirúrgicamente de tumor retroperitoneal / Delayed recurrence of a phaechromocytoma with metastasis as a cause of severe hypertension in a woman with a surgically intervened retroperitoneal tumour

Presentamos el caso de una mujer con antecedentes previos de hipertensión arterial y tumoración retroperitoneal, cuyo estudio anatomopatológico fue de paraganglioma, sin seguimiento clínico. Años después se constató recidiva tumoral del feocromocitoma tras comenzar con hipertensión arterial de difícil control junto con elevación de catecolaminas urinarias. El caso pretende resaltar la importancia de realizar un seguimiento clínico en estos pacientes, por el riesgo de recidiva (AU)

We present the case of a woman with a previous history of hypertension and retroperitoneal tumour. The histology was reported as a paraganglioma. There was no clinical follow-up. Years later, there was a recurrence of the phaeochromocytoma after presenting with a difficult to control hypertension, along with elevation of urinary catecholamines. The case aims to highlight the importance of performing a clinical follow-up in these patients, due to the risk of recurrence (AU)

Factors affecting the incidence of contrast-induced nephropathy in patients undergoing computed tomography. / Incidencia de nefropatía por contraste en pacientes sometidos a tomografía computarizada: ¿qué factores la condicionan?

OBJECTIVE: To analyze the incidence of contrast-induced nephropathy in a cohort of patients undergoing computed tomography (CT) with intravenous iodinated contrast material. To evaluate the efficacy of N-acetylcysteine in preventing contrast-induced nephropathy. PATIENTS AND METHODS: This prospective observational study was carried out in the months comprising March 2016 through July 2016. We selected the first five patients scheduled to undergo CT examination each day who agreed to participate and signed the informed consent form. We recorded patients' cardiovascular histories, chronic treatments, and indications for the CT examination. We measured blood levels of creatinine and urea before and after the CT examination. We used the Modification of Diet in Renal Disease (MDRD-4) equation to estimate the glomerular filtration rate. We analyzed the type and dose of contrast material. We recorded whether N-acetylcysteine was administered before the CT examination. We used SPSS 15.0® to compare means and proportions. Statistical significance was set at p < 0.05. RESULTS: No incidents of contrast-induced nephropathy were detected in any of the 202 patients included [mean age, 63.92 ± 12 years (range 22-87); 57.4% male; 21.8% diabetic; 39.6% hypertensive; 87.1% had MDRD4 ≥ 60 ml/min/1.73 m2 (89.45 ± 14, range 62.36-134.14) and 12.9% had MDRD4 < 60 ml/min/1.73 m2 (45.38 ± 11, range 9.16-58.90)]. The most common indication for CT examinations was oncologic (81.2%). The only contrast agent administered was iopamidol; the mean dose was 107.83 ± 11 ml (range 70-140). The mean interval between pre-CT and post-CT laboratory tests was 4.06 ± 1 days. Only 13 patients received N-acetylcysteine; 9 of these had MDRD < 60 ml/min/1.73 m2 and 4 had MDRD4 ≥ 60 ml/min/1.73 m2 (p = 0.000). CONCLUSIONS: The incidence of contrast-induced nephropathy was not significant in patients with glomerular filtration rates greater than 30 ml/min/1.73 m2: these favorable results might be due to analyzing only scheduled examinations and to using relatively low doses of a "nonionic" iodinated contrast agent.

Potasio sérico al ingreso y mortalidad intrahospitalaria en centenarios / Admission serum potassium and in-hospital mortality in centenarians

No disponible

[Delayed recurrence of a phaechromocytoma with metastasis as a cause of severe hypertension in a woman with a surgically intervened retroperitoneal tumour]. / Recidiva tardía de feocromocitoma con metástasis como causa de hipertensión arterial severa en mujer intervenida quirúrgicamente de tumor retroperitoneal.

We present the case of a woman with a previous history of hypertension and retroperitoneal tumour. The histology was reported as a paraganglioma. There was no clinical follow-up. Years later, there was a recurrence of the phaeochromocytoma after presenting with a difficult to control hypertension, along with elevation of urinary catecholamines. The case aims to highlight the importance of performing a clinical follow-up in these patients, due to the risk of recurrence.

Niveles de potasio sérico y mortalidad a largo plazo en ancianos con hipertensión arterial / Serum potassium levels and long-term mortality in the elderly with hypertension

Existen crecientes evidencias de que pequeñas variaciones dentro del rango normal del potasio, entre 3,5-5mEq/l, se asocian con mortalidad. Objetivo: Conocer si existe asociación entre el nivel de potasio sérico (Ks) basal con la mortalidad en una cohorte de ancianos hipertensos. Pacientes y métodos: Estudio observacional retrospectivo, de pacientes que disponían de Ks en un periodo de estabilidad clínica, durante su reclutamiento entre enero-abril de 2006 y seguidos durante 10 años. Se estudiaron 62 pacientes estables, con edad media de 82,19 ± 6 años (rango 69-97); 74,2% mujeres, 33,9% diabéticos, 20,3% con antecedentes de insuficiencia cardiaca y 19,4% de cardiopatía isquémica; un 44,3% recibían inhibidores de la enzima convertidora de angiotensina (IECA). Se registró la mortalidad acontecida durante 10 años. La estadística se hizo con SPSS15.0. Resultados: Cuarenta y nueve pacientes fueron exitus. El Ks tenía distribución normal. Los niveles medios basales y mediana de Ks fueron de 4,45 ± 0,5 mEq/l (rango de 3,1-5,5 mEq/l). Los niveles basales de Ks eran significativamente mayores en diabéticos y en tomadores de IECA. Los pacientes fallecidos tenían niveles Ks mayores (4,53 ± 0,49 mEq/l versus 4,14 ± 0,40 mEq/l; p = 0,011). La supervivencia por Kaplan Meier demostró que pacientes con Ks superior a la mediana y a P75 presentaron mayor mortalidad. Conclusiones: En nuestro estudio los niveles Ks mayores a 4,45mEq/l se asociaban con mortalidad. En ancianos hipertensos, a la hora de seleccionar tratamiento antihipertensivo, se debería valorar individualmente el uso de IECA, con monitorización estrecha en los niveles de Ks y procurar mantenerlos en el rango medio de la normalidad (< 4,45 mEq/l)

There is increasing evidence that small variations within the normal range (3.5-5 mEq/L) of potassium are associated with mortality. Objective: To determine whether there is an association between serum potassium level (sK) and mortality in a cohort of elderly hypertensive patients. Patients and methods: A retrospective, observational study was conducted on patients who had sK levels available in a period of clinical stability during their recruitment between January and April 2006 and followed-up for 10 years. The study obtained a total of 62 stable patients, with a mean age of 82.19 ± 6 years (range 69-97), with 74.2% women, 33.9% diabetics, 20.3% with a history of heart failure, Ischaemic heart disease was observed in 19.4% and 44.3% received Angiotensin Converting Enzyme (ACE) inhibitors. An analysis was performed on the mortality rate during the 10 year period. The statistics were performed using the SPSS15.0 package. Results: There were 49 deaths. The sK had a normal distribution. Baseline mean sK levels and median were 4.45 ± 0.5 mEq/L (range 3.1-5.5 mEq/L). Baseline sK levels were significantly higher in diabetic patients and patients on ACE inhibitors. The patients that died had higher sK levels (4.53 ± 0.49 mEq/L versus 4.14 ± 0.40 mEq/L, P = .011). Survival estimated using Kaplan Meier showed that patients with sK levels higher than the median and P75 had higher mortality. Conclusions: In our study, sK levels greater than 4.45 mEq/L were associated with mortality. When selecting antihypertensive treatment in hypertensive elderly patients,, the use of ACE inhibitors should be assessed individually, with close monitoring at sK levels and try to keep them in the lower limit of the normal range (< 4.45 mEq/L)

[Serum potassium levels and long-term mortality in the elderly with hypertension]. / Niveles de potasio sérico y mortalidad a largo plazo en ancianos con hipertensión arterial.

There is increasing evidence that small variations within the normal range (3.5-5mEq/L) of potassium are associated with mortality. OBJECTIVE: To determine whether there is an association between serum potassium level (sK) and mortality in a cohort of elderly hypertensive patients. PATIENTS AND METHODS: A retrospective, observational study was conducted on patients who had sK levels available in a period of clinical stability during their recruitment between January and April 2006 and followed-up for 10 years. The study obtained a total of 62 stable patients, with a mean age of 82.19±6 years (range 69-97), with 74.2% women, 33.9% diabetics, 20.3% with a history of heart failure, Ischaemic heart disease was observed in 19.4% and 44.3% received Angiotensin Converting Enzyme (ACE) inhibitors. An analysis was performed on the mortality rate during the 10 year period. The statistics were performed using the SPSS15.0 package. RESULTS: There were 49 deaths. The sK had a normal distribution. Baseline mean sK levels and median were 4.45±0.5mEq/L (range 3.1-5.5 mEq/L). Baseline sK levels were significantly higher in diabetic patients and patients on ACE inhibitors. The patients that died had higher sK levels (4.53±0.49mEq/L versus 4.14±0.40mEq/L, P=.011). Survival estimated using Kaplan Meier showed that patients with sK levels higher than the median and P75 had higher mortality. CONCLUSIONS: In our study, sK levels greater than 4.45mEq/L were associated with mortality. When selecting antihypertensive treatment in hypertensive elderly patients,, the use of ACE inhibitors should be assessed individually, with close monitoring at sK levels and try to keep them in the lower limit of the normal range (<4.45 mEq/L).

Influencia del estado funcional en la mortalidad en ancianos con hipertensión arterial / Influence of functional state in mortality of the elderly with hypertension

No disponible